When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.

BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer.

Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive Crisis.

TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Solid Tumor.

Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

A successful clinical trial requires an effective randomization strategy formulated by innovative thinking to meet unique demands. In a recent webinar, Solventum revealed how the eClinical platform ...

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due for a shake up with new healthcare leaders set to take charge in the US.

Peresolimab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Autoimmune Disorders.